SGLT2 inhibitors may improve glycaemic control and renal markers without affecting body weight in patients with Prader-Willi syndrome and T2D, but they are tied to an elevated risk for adverse events.

Treatment with intranasal carbetocin was not associated with a statistically significant improvement in hyperphagia compared with placebo. Topline results were announced from a phase 3 trial ...

Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with ...

Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook.

SAN DIEGO, September 24, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of ...

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. ACADIA Pharmaceuticals Inc. stands second among them. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a ...

Acadia Pharmaceuticals was testing the drug, an intranasal formulation of the oxytocin analogue carbetocin, for its potential ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the ...

Prader-Willi syndrome is a rare genetic disorder characterized by hyperphagia, an insatiable hunger that can lead to excessive eating and life-threatening obesity. The company maintains a strong ...